Adverse reaction to intravenous gadoteridol.
Moderate and severe anaphylactoid reactions--while extremely rare--have been reported in association with intravenous administration of gadopentetate dimeglumine. There has been no similar experience related to use of the newly released magnetic resonance (MR) imaging contrast agent gadoteridol. The authors describe a case of vasovagal response and anaphylactoid reaction during intravenous administration of gadoteridol. MR users should be aware of the potential for adverse effects to occur in association with use of gadoteridol and be prepared by implementing appropriate observation procedures for patients receiving this as well as other MR contrast agents. In addition, physiologic monitoring devices and resuscitation equipment should be readily available in the clinical MR setting for proper treatment of patients who may experience moderate to severe adverse reactions.
F G
FG
Shellock
H P
HP
Hahn
J H
JH
Mink
E
E
Itskovich
D000328:Adult; D000707:Anaphylaxis / Q000139:chemically induced*; D003287:Contrast Media / Q000008:administration & dosage / Q000009:adverse effects*; D005682:Gadolinium / Q000008:administration & dosage / Q000009:adverse effects*; D006571:Heterocyclic Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D014630:Vagus Nerve / Q000187:drug effects*; D014666:Vasomotor System / Q000187:drug effects*
D003287:Contrast Media; D006571:Heterocyclic Compounds; D009942:Organometallic Compounds; C062402:gadoteridol; D005682:Gadolinium